SEAGEN INC (SGEN) Stock Price & Overview
NASDAQ:SGEN • US81181C1045
Current stock price
The current stock price of SGEN is 228.74 USD. Today SGEN is down by -0.07%. In the past month the price increased by 6.91%. In the past year, price increased by 76.48%.
SGEN Key Statistics
- Market Cap
- 43.154B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.01
- Dividend Yield
- N/A
SGEN Stock Performance
SGEN Stock Chart
SGEN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to SGEN. When comparing the yearly performance of all stocks, SGEN is one of the better performing stocks in the market, outperforming 91.69% of all stocks.
SGEN Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to SGEN. While SGEN has a great health rating, there are worries on its profitability.
SGEN Earnings
SGEN Forecast & Estimates
23 analysts have analysed SGEN and the average price target is 233.48 USD. This implies a price increase of 2.07% is expected in the next year compared to the current price of 228.74.
For the next year, analysts expect an EPS growth of -28.74% and a revenue growth 28.4% for SGEN
SGEN Groups
Sector & Classification
SGEN Financial Highlights
Over the last trailing twelve months SGEN reported a non-GAAP Earnings per Share(EPS) of -4.01. The EPS decreased by -16.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.64% | ||
| ROE | -29.41% | ||
| Debt/Equity | 0 |
SGEN Ownership
SGEN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.26 | 364.897B | ||
| AMGN | AMGEN INC | 15.33 | 183.284B | ||
| GILD | GILEAD SCIENCES INC | 16.01 | 172.309B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.9 | 109.705B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.59 | 80.376B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.86 | 42.375B | ||
| INSM | INSMED INC | N/A | 35.141B | ||
| NTRA | NATERA INC | N/A | 29.66B | ||
| BIIB | BIOGEN INC | 11.19 | 25.773B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.48 | 24.795B | ||
| MRNA | MODERNA INC | N/A | 19.79B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.082B | ||
| INCY | INCYTE CORP | 12.52 | 18.645B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SGEN
Company Profile
Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. The company is headquartered in Bothell, Washington and currently employs 3,256 full-time employees. The company went IPO on 2001-03-07. The firm is engaged in commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers; TUKYSA, or tucatinib, for the treatment of certain metastatic human epidermal growth factor receptor 2 (HER2) -positive breast and colorectal cancers, and TIVDAK, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers. The company is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Its programs including ADCETRIS, PADCEV and TIVDAK, are based on the Company’s antibody-drug conjugate (ADC) technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.
Company Info
IPO: 2001-03-07
SEAGEN INC
21823 30Th Drive Se, Suite
Bothell WASHINGTON 98021 US
CEO: Clay B. Siegall
Employees: 3256
Phone: 14255274000
SEAGEN INC / SGEN FAQ
What does SEAGEN INC do?
Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. The company is headquartered in Bothell, Washington and currently employs 3,256 full-time employees. The company went IPO on 2001-03-07. The firm is engaged in commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers; TUKYSA, or tucatinib, for the treatment of certain metastatic human epidermal growth factor receptor 2 (HER2) -positive breast and colorectal cancers, and TIVDAK, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers. The company is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Its programs including ADCETRIS, PADCEV and TIVDAK, are based on the Company’s antibody-drug conjugate (ADC) technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.
What is the current price of SGEN stock?
The current stock price of SGEN is 228.74 USD. The price decreased by -0.07% in the last trading session.
Does SEAGEN INC pay dividends?
SGEN does not pay a dividend.
What is the ChartMill technical and fundamental rating of SGEN stock?
SGEN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What sector and industry does SEAGEN INC belong to?
SEAGEN INC (SGEN) operates in the Health Care sector and the Biotechnology industry.
What is the Price/Earnings (PE) ratio of SEAGEN INC (SGEN)?
SEAGEN INC (SGEN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.01).
Is SEAGEN INC (SGEN) expected to grow?
The Revenue of SEAGEN INC (SGEN) is expected to grow by 28.4% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.